XORTX Therapeutics Inc. Common Stock
XRTXXORTX Therapeutics Inc. is a biopharmaceutical company focused on developing targeted therapies for kidney diseases, particularly those involving fluid and electrolyte imbalance. The company specializes in innovative treatments for conditions such as autosomal dominant polycystic kidney disease (ADPKD) and other related disorders, leveraging oral therapeutics to improve patient outcomes.
Company News
XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV) to reduce costs and administrative burden. The company will maintain its listings on Nasdaq and Frankfurt. The delisting is expected to eliminate duplicative exchange fees, reduce legal and accounting expenses, and allow management to ...
XORTX Therapeutics has completed its acquisition of the VB4-P5 program from Vectus Biosystems, a novel therapeutic targeting kidney fibrosis in chronic kidney disease. The deal valued at US$3.0 million includes patent rights and preclinical data. VB4-P5 is positioned to address a significant unmet medical need in both rare and prevalent kidney di...
XORTX Therapeutics announced that its 1-for-5 share consolidation has received all required approvals from TSX Venture Exchange and Nasdaq Stock Exchange, effective April 6, 2026. The company is a late-stage clinical pharmaceutical firm developing therapies for gout and progressive kidney disease, with three clinically advanced products in develo...
XORTX Therapeutics Inc. held its annual and special shareholder meeting on March 24, 2026, with 35% shareholder representation. All proposed matters were approved, including the election of five board members (Anthony Giovinazzo as Chair, Allen Davidoff as CEO, Mika Grasso, Richard Grieve, and George Scorsis), appointment of Davidson & Company LL...
XORTX Therapeutics Inc. announced shareholder approval for a 5-to-1 share consolidation to maintain compliance with NASDAQ's listing requirements, specifically ensuring shares trade above $1.00. The consolidation will reduce outstanding shares from approximately 6.96 million to 1.39 million and is pending TSX Venture Exchange approval. The compan...
